No Data
No Data
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients
Express News | Tourmaline Bio Inc: Topline Data Anticipated in First Half of 2025
Express News | Tourmaline Bio Initiates Clinical Development of Tour006 for Cardiovascular Diseases With First Patient Dosed in Phase 2 Tranquility Trial
Truist Financial Reaffirms Their Buy Rating on Tourmaline Bio (TRML)
Express News | HC Wainwright & Co. Reiterates Buy on Tourmaline Bio, Maintains $48 Price Target
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
No Data